Escobar-Pérez X, Lahera-Sánchez T, de Armas-Fernández MC, Blanco-Santana D, Navarro-Pérez L, Calvo-Pérez A, Álvarez-Goyanes RI

Language: Spanish
References: 18
Page: 45-51
PDF size: 221.17 Kb.

ABSTRACT

The tissue microarray (TMA) technique is based on making cylindrical cores from paraffin donor blocks and transfer to a single recipient block. The TMA has revolutionized the field of pathology for the possibility to evaluate multiple samples in one slide. There is no precedent of this subject in Cuba, so the objective of this research was to implement the TMA technique. The concordance of the results obtained by complete section and the TMA were evaluated for this purpose, in the evaluation of the estrogen receptors (ER), progesterone (PR) and epidermal growth factor type 2 (HER2) in samples of breast cancer. Forty-five paraffin-embedded samples from women diagnosed with breast cancer at the Institute of Oncology in 2012 were studied. Two TMA blocks were constructed, and subsequently the expression of markers ER, PR and HER2 was determined by immunohistochemistry, in the complete section of tissue and in the TMA. Kappa index was used for concordance analysis. A good concordance was obtained for all three markers (ER k=0.8272; PR k=0.793 and HER2 k=0.716). This study constitutes the first report on the TMA technique in Cuba and shows that it is a valuable tool, suggesting its potential use in translational research and clinical trials on vaccines.

REFERENCES

1. Thomson T, Zhou C, Chu C, Knight B. Tissue Microarray for Routine Analysis of Breast Biomarkers in the Clinical Laboratory. Am J Clin Pathol 2009;132(6):899-905.

2. Wan WH, Fortuna MB, Furmanski P. A Rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 1987;103(1):121-9.

3. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4(7):844-7.

4. Pinder SE, Brown JP, Gillet C, Purdie CA, Speirs V, Thompson AM, et al. The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example.J Clin Pathol 2013;66(3):169-77.

5. Dolled-Filhart MP, Gustavson MD. Tissue microarrays and quantitative tissue-based image analysis as a tool for oncology biomarker and diagnostic development. Expert Opin Med Diagn 2012;6(6):569-83.

6. Kumar B, De Silva M, Venter DJ, Armes JE. Tissue microarrays: a practical guide. Pathology 2004;36(4):295-300.

7. Ministerio de Salud Pública de Cuba. Dirección Nacional de Estadísticas y Registros Médicos. Anuario Estadístico de Salud 2013. La Habana: MINSAP; 2013.

8. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28(16):2784-95.

9. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists. Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25(1):118-45.

10. Ochoa-Azze RF. Validación de inmunoensayos cuantitativos y cualitativos. En: Ochoa-Azze RF. Técnicas Inmunoenzimáticas en el Desarrollo Clínico de Vacunas. La Habana: Finlay Ediciones; 2013.p.25-41.

11. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003;16(1):79-85.

12. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80(12):1943-9.

13. Gillet CE, Springall RJ, Barnes DM, Hanby AM. Multiple tissue core arrays in histopathology research: a validation study. J Pathol 2000;192(4):549-53.

14. Graham AD, Faratian D, Rae F, Thomas J. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 2008;52(7):847-55.

15. Egervari K, Szollosi Z, Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract. 2007;203(3):169-77.

16. Selvarajan S, Tan SY, Sii LH, Tan PH. c-erbB-2 (HER-2/neu) immunohistochemistry in invasive breast cancer: is there concordance between standard sections and tissue microarrays? Pathology 2006;38(4):316-20.

17. Faratian D, Kay C, Robson T, Campbell FM, Grant M, Read D, et al. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in largescale clinical studies: the TEAM Trial Experience. Histopathology 2009;55(5):587-93.

18. Escobar J, Astudillo A, Menéndez P, Belyakova E. Aplicación de los Tissue Microarrays en el estudio inmunohistoquímico de los tumores. Rev Esp Patol 2006;39(1):11-7.